Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.

Circulating Tumor DNA Feasibility Studies High-Throughput Nucleotide Sequencing / methods Humans Mutation Polymerase Chain Reaction / methods

Journal

Analytical chemistry
ISSN: 1520-6882
Titre abrégé: Anal Chem
Pays: United States
ID NLM: 0370536

Informations de publication

Date de publication:
26 04 2022
Historique:
pubmed: 14 4 2022
medline: 28 4 2022
entrez: 13 4 2022
Statut: ppublish

Résumé

The clinical actionability of circulating tumor DNA requires sensitive detection methods with a short turnaround time. In the PADA-1 phase 3 trial (NCT03079011), metastatic breast cancer patients treated with an aromatase inhibitor and palbociclib were screened every 2 months for activating

Identifiants

DOI: 10.1021/acs.analchem.2c00446 PMID: 35416669
pubmed: 35416669
doi: 10.1021/acs.analchem.2c00446
doi:

Substances chimiques

Circulating Tumor DNA 0

Types de publication

Clinical Trial, Phase III Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6297-6303

Auteurs

Celine Callens (C)

Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.
ORCID: 0000-0003-3377-4937

Francois-Clement Bidard (FC)

Department of Medical Oncology, Institut Curie, UVSQ/Paris Saclay University, 92210 Saint Cloud, France.
Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, 75005 Paris, France.

Anaïs Curto-Taribo (A)

Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.

Olfa Trabelsi-Grati (O)

Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.

Samia Melaabi (S)

Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.

Suzette Delaloge (S)

Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France.

Anne-Claire Hardy-Bessard (AC)

Department of Medical Oncology, Centre Armoricain d'Oncologie, 22190 Plérin, France.

Thomas Bachelot (T)

Department of Medical Oncology, Centre Léon Bérard, 69000 Lyon, France.

Florian Clatot (F)

Department of Medical Oncology, Centre Henri Becquerel, 76000 Rouen, France.

Thibault De La Motte Rouge (T)

Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.

Jean-Luc Canon (JL)

Department of Medical Oncology, Grand Hôpital de Charleroi, 6000 Charleroi, Belgique.

Laurent Arnould (L)

Department of Pathology, Centre Georges François Leclerc, 21000 Dijon, France.

Fabrice Andre (F)

Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France.

Sandrine Marques (S)

Research and Development Department, UNICANCER, 75013 Paris, France.

Marc-Henri Stern (MH)

Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Institut Curie, PSL Research University, 75005 Paris, France.

Jean-Yves Pierga (JY)

Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, 75005 Paris, France.
Department of Medical Oncology, Institut Curie & Université de Paris, 75005 Paris, France.

Anne Vincent-Salomon (A)

Department of Diagnostic and Theranostic Medicine, Institut Curie, 75005 Paris, France.

Camille Benoist (C)

Bio-informatic Clinical Unit, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.

Emmanuelle Jeannot (E)

Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.

Frederique Berger (F)

Biometry Unit, Institut Curie and PSL Research University, 75005 Paris and 92210 Saint-Cloud, France.

Ivan Bieche (I)

Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France.

Anne Pradines (A)

INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, 31000 Toulouse, France.
Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute (IUCT-O), 31000 Toulouse, France.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › ADN tumoral › ADN tumoral circulant › Real-Time Detection of ESR1 Mutation in Blood...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études de faisabilité › Real-Time Detection of ESR1 Mutation in Blood...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Real-Time Detection of ESR1 Mutation in Blood...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Real-Time Detection of ESR1 Mutation in Blood...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Real-Time Detection of ESR1 Mutation in Blood...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Techniques d'amplification d'acides nucléiques › Réaction de polymérisation en chaîne › Real-Time Detection of ESR1 Mutation in Blood...